Lysosomal alpha-glucosidase · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Lysosomal alpha-glucosidase shows approved-linked disease relevance led by diabetes mellitus. 3 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P10253. Start with diabetes mellitus, then reuse UniProt P10253 as the stable protein anchor across project notes and exports.
Start with diabetes mellitus, then reuse UniProt P10253 as the stable protein anchor across project notes and exports.
Lysosomal alpha-glucosidase shows approved-linked disease relevance led by diabetes mellitus. 3 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with diabetes mellitus because it currently carries approved-linked support. Linked drugs include MIGLITOL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyLysosomal alpha-glucosidase
Review this target as Lysosomal alpha-glucosidase, mapped to UniProt P10253. Sequence length is 952 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Lysosomal alpha-glucosidase as ChEMBL target CHEMBL2608, mapped to UniProt P10253. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Lysosomal alpha-glucosidase is the right protein anchor across sources, using UniProt P10253 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why diabetes mellitus is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Lysosomal alpha-glucosidase |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P10253 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Lysosomal alpha-glucosidase |
| UniProt Accession | P10253 |
| Component Type | Protein |
| Sequence Length | 952 aa |
Lysosomal alpha-glucosidase
Review this target as Lysosomal alpha-glucosidase, mapped to UniProt P10253. Sequence length is 952 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Lysosomal alpha-glucosidase shows approved-linked disease relevance led by diabetes mellitus. 3 more disease programs remain visible in the same review block.
Start review with diabetes mellitus because it currently carries approved-linked support. Linked drugs include MIGLITOL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL5028005 | 8.33 | Ki | 4.7 | Preclinical |
| CHEMBL5028265 | 8.21 | Ki | 6.1 | Preclinical |
| CHEMBL86772 | 7.99 | IC50 | 10.3 | Preclinical |
| CHEMBL5029066 | 7.72 | Ki | 19.0 | Preclinical |
| CHEMBL5027974 | 7.43 | Ki | 37.0 | Preclinical |
| CHEMBL307429 | 7.23 | Ki | 59.0 | Clinical |
| CHEMBL5028138 | 7.23 | Ki | 59.0 | Preclinical |
| CHEMBL75971 | 7.23 | Ki | 59.0 | Preclinical |
| CHEMBL307429 | 7.22 | IC50 | 60.0 | Clinical |
| CHEMBL476960 | 7.16 | IC50 | 70.0 | Approved |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 92 | 124 | 5.4 |
| cell-based format | 27 | 5 | 6.5 |
| assay format | 5 | 0 | — |
| tissue-based format | 3 | 0 | — |
| subcellular format | 1 | 2 | 6.4 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 10 | 0 | — |
| organism-based format | 3 | 0 | — |